- Home
- VIAV vs AKRO Comparison
VIAV vs AKRO Comparison
Compare VIAV & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIAV
- AKRO
- Stock Information
- Founded
- VIAV 1923
- AKRO 2017
- Country
- VIAV United States
- AKRO United States
- Employees
- VIAV N/A
- AKRO N/A
- Industry
- VIAV Semiconductors
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- VIAV Technology
- AKRO Health Care
- Exchange
- VIAV Nasdaq
- AKRO Nasdaq
- Market Cap
- VIAV 2.2B
- AKRO 1.8B
- IPO Year
- VIAV 1993
- AKRO 2019
- Fundamental
- Price
- VIAV $11.60
- AKRO $51.84
- Analyst Decision
- VIAV Buy
- AKRO Strong Buy
- Analyst Count
- VIAV 10
- AKRO 9
- Target Price
- VIAV $12.89
- AKRO $75.86
- AVG Volume (30 Days)
- VIAV 3.1M
- AKRO 2.2M
- Earning Date
- VIAV 01-30-2025
- AKRO 03-03-2025
- Dividend Yield
- VIAV N/A
- AKRO N/A
- EPS Growth
- VIAV N/A
- AKRO N/A
- EPS
- VIAV N/A
- AKRO N/A
- Revenue
- VIAV $1,007,000,000.00
- AKRO N/A
- Revenue This Year
- VIAV $10.56
- AKRO N/A
- Revenue Next Year
- VIAV $7.78
- AKRO N/A
- P/E Ratio
- VIAV N/A
- AKRO N/A
- Revenue Growth
- VIAV N/A
- AKRO N/A
- 52 Week Low
- VIAV $6.60
- AKRO $17.86
- 52 Week High
- VIAV $12.91
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- VIAV 51.11
- AKRO 65.39
- Support Level
- VIAV $12.11
- AKRO $48.70
- Resistance Level
- VIAV $12.38
- AKRO $51.40
- Average True Range (ATR)
- VIAV 0.36
- AKRO 2.29
- MACD
- VIAV -0.10
- AKRO -0.90
- Stochastic Oscillator
- VIAV 2.34
- AKRO 35.50
About VIAV Viavi Solutions Inc.
Viavi Solutions Inc. is a global provider of network test, monitoring and assurance solutions to communications service providers, enterprises, network equipment manufacturers, civil government, military and avionics customers. The company also offers high-performance thin-film optical coatings, providing light management solutions to anti-counterfeiting, 3D sensing, electronics, automotive, defense and instrumentation markets. Its operating segments include Network Enablement, Service Enablement, and Optical Security and Performance Products. Geographically, it derives a majority of revenue from the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.